




I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231 on September 6, 2002.

  
Frank C. Eisenschenk, Ph.D., Patent Attorney

RESPONSE UNDER 37 C.F.R. § 1.111  
Examining Group 1655  
Patent Application  
Docket No. GEN-T124X  
Serial No. 09/416,384

*CP/1637  
#28  
NE  
Eisensch  
9.17.02*  
**RECEIVED**

SEP 16 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

Examiner : Jeffrey Fredman, Ph.D.  
Art Unit : 1637  
Applicants : Marta Blumenfeld, Lydie Bougueleret, Ilya Chumakov,  
Daniel Cohen, Laurent Essioux  
Serial No. : 09/416,384  
Filed : October 12, 1999  
Confirm. No. : 6101  
For : GENES, PROTEINS AND BIALLELIC MARKERS RELATED  
TO CENTRAL NERVOUS SYSTEM DISEASE

Assistant Commissioner for Patents  
Washington, D.C. 20231

RESPONSE UNDER 37 C.F.R. § 1.111

In response to the Office Action dated June 6, 2002, Applicants respectfully request that the Examiner reconsider the above-captioned application in view of the following comments.

Claims 58, 62, and 73-75 are currently before the Examiner for his consideration. Favorable consideration of the pending claims is respectfully requested.

Rejection under 35 U.S.C. § 101:

In the Office Action dated June 6, 2002, the Examiner maintains his rejection of claims 58, 62, and 73-75 under 35 U.S.C. § 101 for allegedly lacking utility. Specifically, the Examiner asserts